s

What is an Anti-idiotypic Antibody?

s

Technical articles featuring applications of anti-idiotypic antibodies.

s

Request Bulk Quote
Follow us on:

Facebook Linkedin YouTube WeChat

Antibodies for bioanalysis and drug monitoring of tremelimumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug tremelimumab (Imjudo®) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to tremelimumab and the tremelimumab/CTLA-4 complex
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch-to-batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Tremelimumab.

Specificity Binding Type Catalog Number Clone Format Affinity* KD, nM Assay Recommendation Product Details
Tremelimumab Inhibitory Type 1 TZA0126 AbD64576ad Fab-F-Spy2-H1 <0.02 PK bridging ELISA (capture) Order TZA0126
TZA0127 AbD64580ad Fab-F-Spy2-H1 0.2 PK bridging ELISA (detection) Order TZA0127
TZA0127P AbD64580pap Fab2-FH-X22-HRP2 0.2 PK bridging ELISA (detection) Order TZA0127P
Tremelimumab
/CTLA-4 Complex
Specific Type 3 		TZA0128 AbD64586ad

Fab-F-Spy2-H1

23 PK ELISA antigen capture format Order TZA0128
TZA0128P AbD64586pap Fab2-FH-X22-HRP2 23 PK ELISA antigen capture format Order TZA0128P

* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.

Anti-Tremelimumab Inhibitory Antibodies (Type 1)

Type 1 anti-tremelimumab antibodies inhibit the binding of the drug tremelimumab to its target, cytotoxic T-lymphocyte associated protein 4 (CTLA-4). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format, they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Tremelimumab CTLA-4 Complex-Specific Antibodies (Type 3)

The Type 3 antibodies specifically recognize the drug-target complex, detecting tremelimumab only when it is bound to CTLA-4. They are suitable as a detection antibody in a PK antigen capture assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK Bridging ELISA, Free Drug: TZA0126 (capture) and TZA0127/TZA0127P (detection)

Fig. 1. Tremelimumab PK bridging ELISA using antibodies TZA0126 (capture) and TZA0127P (detection).

Fig. 1. Tremelimumab PK bridging ELISA using antibodies TZA0126 (capture) and TZA0127P (detection).

Schematic image of PK bridging ELISA measuring free drug

Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.

PK Antigen Capture

PK Antigen Capture ELISA: CTLA-4 (capture) and TZA0128 (detection)

PK Antigen Capture ELISA: CTLA-4 (capture) and TZA0128P (detection)

Fig. 2. Tremlimumab PK antigen capture ELISA using CTLA-4 and TZA0128P.

Fig. 2. Tremlimumab PK antigen capture ELISA using CTLA-4 and TZA0128P.

Schematic image of PK antigen capture ELISA.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.